John Spencer - 01 Jul 2026 Form 4 Insider Report for ORAGENICS INC (OGEN)

Reporting relationship: Chief Financial Officer
Issuer ticker: OGEN
Reported as of: 01 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Jul 2026, 17:51:02 UTC
Source filing: View source filing
Reporting owner signature: /s/ Julio C. Esquivel as Attorney-In-Fact for Reporting Person

Key filing fact

John Spencer filed Form 4 for ORAGENICS INC (OGEN) on 07 Jul 2026.

Key facts

This page summarizes John Spencer's Form 4 filing for ORAGENICS INC (OGEN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 07 Jul 2026, 17:51.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002144116 Primary reporting owner

Spencer John

Relationship: Chief Financial Officer
Address: 9015 TOWN CENTER PARKWAY, SUITE 143, LAKEWOOD RANCH
Signature: /s/ Julio C. Esquivel as Attorney-In-Fact for Reporting Person
Signature date: 07 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OGEN transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +55,900
Change %
Price: $0.000000^*
Shares after: 55,900
Date: 01 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 55,900
Exercise price: $0.5900
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended. One fifth of the options vest on the grant date and the remainder of the options subsequently vest in equal annual installments over the first, second, third and fourth anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the Company's closing price on the date of grant.